The KAMILLA trial, a single-arm phase IIIb study of T-DM1 in patients with HER2-positive locally advanced/metastatic breast cancer with prior HER2-targeted therapy and chemotherapy, showed the efficacy and safety of T-DM1 in HER2-positive BCBM. The gene discussed is ERBB2; the disease is breast cancer.